An observational study in Hemorrhage, sponsored by University of Zurich. Completed at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2020-11-12.
Sponsored by University of Zurich · Observational
Study the influence of transfusion related Patient Blood Management Program actions on transfusion-related outcome measures and cost.
At the University Hospital of Zurich, an in-house designed monitoring and feedback system was introduced which electronically registers each transfusion of any allogeneic blood product, be it red blood cells, plasma or platelets as well as corresponding laboratory data. Results are reported quarterly to Department heads. The investigator analyzes whether the introduction of this monitoring and feedback system as part of a patient blood management Program has a significant influence on use of allogeneic blood product transfusions and transfusion-related costs, without compromising patient outcome.
3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.
This study's enrollment of 250,000 is above the median of 150 across 893 observational studies indexed under Hemorrhage.
Browse Hemorrhage studies →University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All cases of all in hospital patients. Area of Focus: Transfusions of blood products.
Exclusion Criteria:
All Health Conditions. Area of Focus: Transfusions of blood products.
Percentage of transfusions per participant
Participant wich had transfusion will be identified and the administrative, financial and clinical data will be compared to participants without transfusions
Time frame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Percentage of transfusion of any blood product per participant
Count of any blood products per case, QM Data
Time frame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Cost of any blood product per participant
costs per case
Time frame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Survey of Patient Blood Management System
clinical, financial,and administrative data of all participants will be reviewed on the focus on transfusions
Time frame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich